Pegylated liposomal doxorubicin (Doxil®) for metastatic breast cancer: The Cancer Research Network, Inc., experience

Cancer Investigation

Volumn 20, Issue SUPPL. 2, 2002, Pages 22-29

  Perez, Alejandra T ^a   Domenech, Gabriel H ^a   Frankel, Cynthia ^a   Vogel, Charles L ^a  

^a NONE   (United States)

Author keywords

Anthracycline; Chemotherapy; Doxorubicin; Drug delivery; Liposome; Metastatic breast cancer; Pegylated liposomal doxorubicin

Indexed keywords

CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; EVACET; GEMCITABINE; MACROGOL; NAVELBINE; TAXANE DERIVATIVE; TRASTUZUMAB;

ACUTE TOXICITY; ADULT; AGED; ANEMIA; ANOREXIA; BONE PAIN; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; NAUSEA; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA;

EID: 0036420885     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/cnv-120014883     Document Type: Conference Paper

References (26)

1. Hortobagyi, G.N. Treatment of breast cancer. N. Engl. J. Med. 1998, 339 (14), 974-984.
2. Gabizon, A.; Chisin, R.; Amselem, S.; Druckmann, S.; Cohen, R.; Goren, D.; Fromer, I.; Peretz, T.; Sulkes, A.; Barenholz, Y. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br. J. Cancer 1991, 64 (6), 1125-1132.
3. Gabizon, A.A. Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Investig. 2001, 19 (4), 424-436.
4. Allen, T.M.; Chonn, A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 1987, 223 (1), 42-46.
5. Gabizon, A.; Catane, R.; Uziely, B.; Kaufman, B.; Safra, T.; Cohen, R.; Martin, F.; Huang, A.; Barenholz, Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54 (4), 987-992.
6. Hong, R.L.; Tseng, Y.L. Phase I and pharmacokinetic study of a stable polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: The relation between pharmacokinetic property and toxicity. Cancer 2001, 91 (9), 1826-1833.
7. Lyass, O.; Uziely, B.; Ben-Yosef, R.; Tzemach, D.; Heshing, N.I.; Lotem, M.; Brufman, G.; Gabizon, A. correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000, 89 (5), 1037-1047.
8. Northfelt, D.W.; Martin, F.J.; Working, P.; Volberding, P.A.; Russell, J.; Newman, M.; Amantea, M.A.; Kaplan, L.D. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with aids-related Kaposi's sarcoma. J. Clin. Pharmacol. 1996, 36 (1), 55-63.
9. Harrington, K.J.; Mohammadtaghi, S.; Uster, P.S.; Glass, D.; Peters, A.M.; Vile, R.G.; Stewart, J.S. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer Res. 2001, 7 (2), 243-254.
10. Symon, Z.; Peyser, A.; Tzemach, D.; Lyass, O.; Sucher, E.; Shezen, E.; Gabizon, A. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 1999, 86 (1), 72-78.
11. Keller, A.M.; Mennel, R.G.; Nabholtz, J.; Georgoulias, V.; Emanuel, D.J.; Tendler, C.L. Phase III trial of pegylated liposomal doxorubicin (Caelyx/Doxil) for the treatment of patients with advanced breast cancer who have failed a prior taxane-containing chemotherapy regimen. Proc. Am. Soc. Clin. Oncol. 2001, 20, 30a, Abstract 115.
12. Ranson, M.R.; Carmichael, J.; O'Byrne, K.; Stewart, S.; Smith, D.; Howell, A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial. J. Clin. Oncol. 1997, 15 (10), 3185-3191.
13. Modiano, M.; Taylor, C.; Sharpington, T. Phase I study of Doxil® (pegylated liposomal doxorubicin) plus escalating doses of taxol in the treatment of patients with advanced breast or gynecologic malignancies. Proc. Am. Soc. Clin. Oncol. 1999, 18, 220a, Abstract 848.
14. Schwonzen, M.; Kurbacher, C.M.; Mallmann, P. Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs 2000, 11 (9), 681-685.
15. Sparano, J.A.; Malik, U.; Rajdev, L.; Sarta, C.; Hopkins, U.; Wolff, A.C. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J. Clin. Oncol. 2001, 19 (12), 3117-3125.
16. Wasserheit, C.; Downey, A.; Sorich, J.; Liebes, L.; Hochster, H.; Oratz, R.; Eisenberg, T.; Losev, A.; Muggia, F. A Phase I study of taxotere and doxil in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. 1999, 18, 167a, Abstract 642.
17. Woll, P.J.; Carmichael, J.; Calvert, A.H.; Ranson, M.; Miles, D.; Chan, S. Doxil®/Caelyx™ (D) plus paclitaxel (T) in patients with metastatic breast cancer (Mbca): Update of a phase II efficacy and safety study. Proc. Am. Soc. Clin. Oncol. 2001, 20, 67b, Abstract 2017.
18. Holder, L.; Overmoyer, B.; Silverman, P.; Tripathy, D.; Marrs, N.; Teitelbaum, A.H. Doxil® and oral cyclophosphamide as first-line therapy for patients with metastatic breast cancer (Mbc): Preliminary Results of a pilot trial. Proc. Am. Soc. Clin. Oncol. 1998, 17, 146a, Abstract 556.
19. Silverman, P.; Overmoyer, B.; Holder, L.; Tripathy, D.; Marrs, N.; Sharpington, T. Doxil® and intravenous cyclophosphamide as first-line therapy for patients with metastatic breast cancer (Mbc): Interim results of an ongoing trial. Proc. Am. Soc. Clin. Oncol. 1999, 18, 115a, Abstract 435.
20. Burstein, H.J.; Ramirez, M.J.; Petros, W.P.; Clarke, K.D.; Warmuth, M.A.; Marcom, P.K.; Matulonis, U.A.; Parker, L.M.; Harris, L.N.; Winer, E.P. Phase I study of doxil and vinorelbine in metastatic breast cancer. Ann. Oncol. 1999, 10 (9), 1113-1116.
21. Rivera, E.; Valero, V.; Syrewicz, L.; Rahman, Z.; Esteva, F.L.; Theriault, R.L.; Rosales, M.M.; Booser, D.; Murray, J.L.; Bast, R.C., Jr.; Hortobagyi, G.N. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J. Clin. Oncol. 2001, 19 (6), 1716-1722.
22. Sparano, J.A.; Winer, E.P. Liposomal anthracyclines for breast cancer. Semin. Oncol. 2001, 28 (4 Suppl. 12), 32-40.
23. Working, P.K.; Newman, M.S.; Sullivan, T.; Yarrington, J. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. J. Pharmacol. Exp. Ther. 1999, 289 (2), 1128-1133.
24. Berry, G.; Billingham, M.; Alderman, E.; Richardson, P.; Torti, F.; Lum, B.; Patek, A.; Martin, F.J. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in aids Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann. Oncol. 1998, 9 (7), 711-716.
25. Safra, T.; Muggia, F.; Jeffers, S.; Tsao-Wei, D.D.; Groshen, S.; Lyass, O.; Henderson, R.; Berry, G.; Gabizon, A. Pegylated liposomal doxorubicin (Doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 Mg/M2. Ann. Oncol. 2000, 11 (8), 1029-1033.
26. Ranson, M.R.; Cheeseman, S.; White, S.; Margison, J. Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. Crit. Rev. Oncol. Hematol. 2001, 37 (2), 115-120.